Waxman/Hatch Reforms Still Allow Multiple 30-Month Stays, PhRMA Says
Executive Summary
FDA should "clarify" that Waxman/Hatch reforms included in the Medicare law still allow for more than one 30-month stay on ANDA approval in some cases, the Pharmaceutical Research & Manufacturers of America said in comments submitted to FDA's generic drugs docket
You may also be interested in...
Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms
Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says
Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms
Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says
FDA Will Create “Limited” Rx Import System, Ex-CMS Head Predicts
The Bush Administration will initiate a "limited" pharmaceutical importation program during 2004, former Centers for Medicare & Medicaid Services Administrator Tom Scully predicted during the Medco drug trend symposium May 18 in Lake Buena Vista, Fla